of Shareholders
MEETING DATE
RECONCILED · MIXED
Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.
ITEM-BY-ITEM RECOMMENDATIONS
The Board of Directors unanimously recommends a vote FOR all nominees.
The filing states there were no disagreements with EY during 2024, 2025, and through the date of change.
The filing states a significant portion of total compensation is tied to corporate and individual objectives.
The filing states important drug development and approval milestones do not occur every calendar year.
Search company, ticker, executive, director or issue